Lars Gedda
Researcher at Department of Chemistry - Ångström Laboratory; Physical Chemistry
- Mobile phone:
- +46 18 471 36 35
- E-mail:
- lars.gedda@kemi.uu.se
- Visiting address:
- Husargatan 3
SE-752 37 Uppsala
Sweden - Postal address:
- Fysikalisk kemi Box 573
SE-752 37 Uppsala
Sweden
More information is available to staff who log in.
Publications
Recent publications
- Dual centrifugation as a novel and efficient method for the preparation of lipodisks (2024)
- Investigation of supramolecular structures in various aqueous solutions of an amyloid forming peptide using small-angle X-ray scattering (2024)
- A closer look at calcium-induced interactions between phosphatidylserine-(PS) doped liposomes and the structural effects caused by inclusion of gangliosides or polyethylene glycol- (PEG) modified lipids (2024)
- Spontaneous Formation of Ultrasmall Unilamellar Vesicles in Mixtures of an Amphiphilic Drug and a Phospholipid (2023)
- Tailoring the Lamellarity of Liposomes Prepared by Dual Centrifugation (2023)
All publications
Articles
- Dual centrifugation as a novel and efficient method for the preparation of lipodisks (2024)
- Investigation of supramolecular structures in various aqueous solutions of an amyloid forming peptide using small-angle X-ray scattering (2024)
- A closer look at calcium-induced interactions between phosphatidylserine-(PS) doped liposomes and the structural effects caused by inclusion of gangliosides or polyethylene glycol- (PEG) modified lipids (2024)
- Spontaneous Formation of Ultrasmall Unilamellar Vesicles in Mixtures of an Amphiphilic Drug and a Phospholipid (2023)
- Tailoring the Lamellarity of Liposomes Prepared by Dual Centrifugation (2023)
- Excited-state and charge-carrier dynamics in binary conjugated polymer dots towards efficient photocatalytic hydrogen evolution (2023)
- Vesicle-enriched secretomes alter bacterial competitive abilities and are drivers of evolution in microbial communities (2023)
- Polymer Dots as Photoactive Membrane Vesicles for [FeFe]-Hydrogenase Self-Assembly and Solar-Driven Hydrogen Evolution (2022)
- Influence of Chain Length of Gradient and Block Copoly(2-oxazoline)s on Self-Assembly and Drug Encapsulation (2022)
- Structural Characterization Study of a Lipid Nanocapsule Formulation Intended for Drug Delivery Applications Using Small-Angle Scattering Techniques (2022)
- Investigation of the enhanced ability of bile salt surfactants to solubilize phospholipid bilayers and form mixed micelles. (2021)
- Panchromatic Ternary Polymer Dots Involving Sub-Picosecond Energy and Charge Transfer for Efficient and Stable Photocatalytic Hydrogen Evolution (2021)
- Formulation development and upscaling of lipid nanocapsules as a drug delivery system for a novel cyclic GMP analogue intended for retinal drug delivery (2021)
- Effect of gangliosides on structure and integrity of polyethylene glycol(PEG)-stabilized liposomes (2020)
- Tumor-Targeted Delivery of the p53-Activating Peptide VIP116 with PEG-Stabilized Lipodisks (2020)
- Osmoprotective effect of ubiquinone in lipid vesicles modelling the E. coli plasma membrane (2019)
- EGF-targeting lipodisks for specific delivery of poorly water-soluble anticancer agents to tumour cells (2017)
- 17AAG-induced internalisation of HER2- specific Affibody molecules (2016)
- Characterization of recombinant human bone morphogenetic protein-2 delivery from injectable hyaluronan-based hydrogels by means of I-125-radiolabelling (2014)
- Pre-incubation of chemically crosslinked hyaluronan-based hydrogels, loaded with BMP-2 and hydroxyapatite, and its effect on ectopic bone formation (2014)
- Resolving the EGF-EGFR interaction characteristics through a multiple-temperature, multiple-inhibitor, real-time interaction analysis approach (2013)
- Evaluation of Real-Time Immunohistochemistry and Interaction Map as an Alternative Objective Assessment of HER2 Expression in Human Breast Cancer Tissue (2013)
- Morphological differences in BMP-2-induced ectopic bone between solid and crushed hyaluronan hydrogel templates (2013)
- Improved bone formation by altering surface area of hyaluronan-based hydrogel carrier for bone morphogenetic protein-2 (2012)
- The HER2-binding Affibody Molecule (ZHER2:342)2 Increases Radiosensitivity in SKBR-3 cells (2012)
- Generation and Evaluation of Bispecific Affibody Molecules for Simultaneous Targeting of EGFR and HER2 (2012)
- Nuclisome (2012)
- Experimental radionuclide therapy of HER2-expressing xenografts using two-step targeting Nuclisome-particles (2012)
- Cellular effects of HER3-specific affibody molecules (2012)
- The importance of proper protein handling and detection for the design of a BMP-2 release system (2012)
- Avoiding false negative results in specificity analysis of protein-protein interactions (2011)
- Comparing the epidermal growth factor interaction with four different cell lines (2011)
- Gefitinib Induces Epidermal Growth Factor Receptor Dimers Which Alters the Interaction Characteristics with (125)I-EGF (2011)
- In vitro evaluation and biodistribution of HER2-targeted liposomes loaded with an 125I-labelled DNA-intercalator (2011)
- Combining phage and staphylococcal surface display for generation of ErbB3-specific Affibody molecules (2011)
- Oncolytic adenovirus modified with somatostatin motifs for selective infection of neuroendocrine tumor cells (2011)
- Nuclisome (2010)
- Real-time immunohistochemistry analysis of embedded tissue (2010)
- Blocking EGFR in the liver improves the tumor-to-liver uptake ratio of radiolabeled EGF (2010)
- Engineering and characterization of a bispecific HER2 x EGFR-binding affibody molecule (2009)
- Flow cytometric in situ proximity ligation analyses of protein interactions and post-translational modification of the epidermal growth factor receptor family (2009)
- Hsp90 is expressed and represents a therapeutic target in human oesophageal cancer using the inhibitor 17-allylamino-17-demethoxygeldanamycin (2009)
- Targeting EGFR and HER2 with 211At-labeled molecules (2008)
- Dimeric HER2-specific affibody molecules inhibit proliferation of the SKBR-3 breast cancer cell line (2008)
- [Lu-177]pertuzumab (2007)
- In vitro evaluation of two polyhedral boron anion derivatives as linkers for attachment of radioiodine to the anti-HER2 monoclonal antibody trastuzumab (2007)
- Penetration of tumor therapy interesting substances in non-vascularized metastases; Review of studies in cellular spheroids (2006)
- Penetration of tumor therapy interesting substances in non-vascularized metastases. (2006)
- Planning for intracavitary anti-EGFR radionuclide therapy of gliomas (2006)
- A novel I-125-labeled daunorubicin derivative for radionuclide-based cancer therapy (2006)
- Astatinated trastuzumab, a putative agent for radionuclide immunotherapy of ErbB2-expressing tumours (2006)
- 111In-benzyl-DTPA-ZHER2:342, an affibody-based conjugate for in vivo imaging of HER2 expression in malignant tumors (2006)
- Identification and characterization of a novel splicing variant of vesicular monoamine transporter 1 (2005)
- An Aminoacridine Derivative for Radionuclide Therapy: Dna-Binding Properties Studied in a Novel Cell-Free in vitro Assay (2005)
- An aminoacridine derivative for radionuclide therapy (2005)
- EGF-receptor targeted liposomes with boronated acridine (2005)
- [(177)Lu]pertuzumab (2005)
- Radionuklidterapi - möjlig väg mot bättre behandling av cancer (2004)
- [177Lu]Bz-DTPA-EGF (2004)
- Comparative biodistribution of potential anti-glioblastoma conjugates [111In]DTPA-hEGF and [111In]Bz-DTPA-hEGF in normal mice (2004)
- Introductory experiments on ligand liposomes as delivery agents for boronneutron capture therapy (2003)
- Ligand liposomes and boron neutron capture therapy (2003)
- Tumor-cell targeted EGF liposomes loaded with boronated acridine (2003)
- Combined effect of gefitinib ('Iressa', ZD1839) and targeted radiotherapy with 211At-EGF (2003)
- Cellular retention of radioactivity and increased radiation dose (2003)
- [111In]Bz-DTPA-hEGF (2003)
- Trastuzumab-conjugated boron-containing liposomes for tumor-celltargeting; development and cellular studies. (2003)
- Development of EGF-conjugated liposomes for targeted delivery of boronated DNA-binding agents (2002)
- [111In]-DTPA-hEGF and [111In]-Bz-DTPA-hEGF (2002)
- A new antibody recognizing the vIII mutation of human epidermal growthfactor receptor. (2002)
- Internalisation and retention of EGF-dextran associated radioactivity intransfected Chinese hamster ovary cells expressing the human EGF-receptor. (2002)
- Comparative biodistribution of the radiohalogenated (Br, I and At) antibody A33 (2002)
- [111In] benzyl-DTPA-EGF, a new potential radiopeptide for targeting of glioma (2002)
- Cellular processing of iodinated and astatinated trastuzumab in cultured SK-BR-3 breast cancer cells (2002)
- Effects of dextranation on the uptake of peptides in micrometastases:studies on binding of EGF in tumor spheroids. (2001)
- The influence of lipophilicity on binding of boronated DNA-intercalatingcompounds in human glioma spheroids. (2000)
- The influence of lipophilicity on binding of boronated DNA-intercalating compounds in human glioma speroids (2000)
- Synthesis of [211At] N-[8-(acridin-9-ylamino)-octyl]-3- astatobenzamide, an astatinated DNA intercalator (2000)
- Cellular processing of (125)I- and (111)in-labeled epidermal growth factor(EGF) bound to cultured A431 tumor cells (2000)
- Cellular processing of 125I- and 111in-labeled epidermal growth factor (EGF) bound to cultured A431 tumor cells (2000)
- Conjugate chemistry and cellular processing of EGF-dextran (1999)
- Closo-dodecaborate(2-) as a linker for iodination of macromolecules (1999)
- Cytotoxicity and subcellular localization of boronated phenanthridinium analogues. (1998)
- Uptake of a boronated epidermal growth factor-dextran conjugate in CHOtor expression. (1998)
- Conjugate chemistry, iodination and cellular binding of mEGF-dextran-tyrosine: preclinical tests in preparation for clinicaltrials (1998)
- Epidermal growth factor-DNA conjugate for two-step targeting: development and introductory in vitro evaluation. (1997)
- Penetration and Binding of EGF-Dextran Conjugates in Cultured-Cell Spheroids (1997)
- Chemistry and biology of some low molecular weight boron compounds forboron neutron capture therapy. (1997)
- Labelling of boron containing compounds with halogen isotopes (1997)
- Development and in vitro studies of epidermal growth factor-dextranconjugates for boron neutron capture therapy. (1996)
- Two-step targeting: EGF-based conjugate for deliverance of nucleus-specific boron compounds. (1996)
- In vitro and in vivo studies of a boronated epidermal growth factor (EGF)-dextran conjugate (1996)
- Carboranyl phenanthridinium analogues: synthesis and biological evaluation. (1996)
- Strategy for boron neutron capture therapy against tumor cells with over-expression of the epidermal growth factor-receptor. (1994)
- Influence of liposome composition on cellular drug delivery and therapeutic effect mediated by Nuclisome-particles
- Improved bone formation through increased surface area of hyaluronan-based hydrogels when used as carriers for BMP-2
- Synthesis, radioiodination, DNA binding and cellular uptake of some doxorubicin analogues
Books
Chapters
- The Auger effect in molecular targeting therapy. (2008)
- SLT-particles for two step targeting in boron neutron capture therapy (2001)
- Stabilised Liposomes with Double Targeting for Use in BNCT (2000)
- Boron neutron capture therapy against tumor cells with overexpression of the EGF-receptor (1996)
- Preparation of epidermal growth factor conjugates aimed for boron neutron capture therapy. (1996)
- Synthesis and initial biological evaluation of carborane-containing phenanthridinium derivatives. (1996)
Conferences
- Preclinical research on Auger therapy (2003)
- Cellular spheroids as a micrometastasis model in preclinical tests of boron neutron capture therapy (2001)
- Stabilised liposomes with double targeting intendent for use in BNCT (2001)
- SLT-particles for two-step targeting in boron neutron capture therapy (2001)
- Two step targeting: EGF-conjugate for delivery of DNA-binding compounds. (1997)
- In vitro and in vivo studies of a boronated epidermal growth factor (EGF)-dextran conjugate. (1997)
- Carboranyl phenantridinium analogues: Synthesis and biological evaluation. (1997)